Education
About Us
Working with TipRanks
Follow Us
PTC Therapeutics (PTCT)
NASDAQ:PTCT
PTCT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$25.67 - $58.38
Previous CloseN/A
Volume146.45K
Average Volume (3M)1.08M
Market Cap
$3.91B
Enterprise Value$2.73B
Total Cash (Recent Filing)$54.75M
Total Debt (Recent Filing)$3.84M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
May 06, 2025EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.73
Shares Outstanding78,869,370
10 Day Avg. Volume1,118,450
30 Day Avg. Volume1,078,000
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.59
Price to Cash Flow (P/CF)-37.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.39
Enterprise Value/Ebitda-21.86
Forecast
1Y Price Target
$66.70Price Target Upside34.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityPTCT is well prepared to handle macro uncertainties with a strong cash balance of more than $2bn.
Market ExpansionThe company remains focused on continuing to expand Translarna’s commercial footprint in growth markets, including further expansion into South America, North Africa, and the Middle East, and emergence into new Asia-Pacific markets like Japan.
Regulatory ProgressLabeling discussions for the PKU program have begun early, potentially allowing for earlier approval and showcasing high enthusiasm.
Bears Say
Market UncertaintyThe US opportunity for Translarna currently sits outside of the model, indicating uncertainty in the market potential there.
Product EffectivenessThe CHMP concluded that the effectiveness of Translarna has not been confirmed.
Regulatory ChallengesThe European Commission has adopted the final negative opinion from the Committee for Medicinal Products for Human Use, effectively removing Translarna's conditional marketing authorization in the EU.
---
Ownership Overview
1.33% Insiders
24.76% Mutual Funds
0.50% Other Institutional Investors
55.75% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PTCT FAQ
What was PTC Therapeutics’s price range in the past 12 months?
PTC Therapeutics lowest stock price was $25.67 and its highest was $58.38 in the past 12 months.
What is PTC Therapeutics’s market cap?
PTC Therapeutics’s market cap is $3.91B.
When is PTC Therapeutics’s upcoming earnings report date?
PTC Therapeutics’s upcoming earnings report date is May 06, 2025 which is in 10 days.
How were PTC Therapeutics’s earnings last quarter?
PTC Therapeutics released its earnings results on Feb 27, 2025. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.54 by -$0.31.
Is PTC Therapeutics overvalued?
According to Wall Street analysts PTC Therapeutics’s price is currently Undervalued.
Does PTC Therapeutics pay dividends?
PTC Therapeutics does not currently pay dividends.
What is PTC Therapeutics’s EPS estimate?
PTC Therapeutics’s EPS estimate is -1.01.
How many shares outstanding does PTC Therapeutics have?
PTC Therapeutics has 78,869,370 shares outstanding.
What happened to PTC Therapeutics’s price movement after its last earnings report?
PTC Therapeutics reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.54. Following the earnings report the stock price went up 9.274%.
Which hedge fund is a major shareholder of PTC Therapeutics?
Currently, no hedge funds are holding shares in PTCT
---
PTC Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$66.70 (34.61% Upside)
$66.70 (34.61% Upside)
Blogger Sentiment
Bullish
PTCT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $512.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
96.54%
12-Months-Change
Fundamentals
Return on Equity
33.08%
Trailing 12-Months
Asset Growth
-9.79%
Trailing 12-Months
Company Description
PTC Therapeutics
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
---
PTCT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
PTC Therapeutics had a strong 2024 with notable financial performance, successful regulatory achievements, and strategic partnerships. However, there are challenges and uncertainties in regulatory approvals and market conditions that may impact future performance.Read More>---
PTCT Stock 12 Month Forecast
Average Price Target
$66.70
▲(34.61% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Rhythm Pharmaceuticals
―
Springworks Therapeutics
―
Avidity Biosciences
―
Arcellx Inc
―
Best Analysts Covering PTCT
1 Year
1 Year Success Rate
14/17 ratings generated profit
1 Year Average Return
+33.37%
reiterated a buy rating 5 months ago
Copying Joel Beatty's trades and holding each position for 1 Year would result in 82.35% of your transactions generating a profit, with an average return of +33.37% per trade.
---